Institute Of Hematology And Blood Transfusion To Present Use Of Applied DNA's Linea DNATM For Non-Viral Manufacture Of CAR T-Cell Therapy For Refractory AML
Portfolio Pulse from Benzinga Newsdesk
The Institute of Hematology and Blood Transfusion will present its use of Applied DNA's Linea DNATM technology for the non-viral manufacture of CAR T-cell therapy aimed at treating refractory AML. This showcases a significant application of Applied DNA's technology in advancing cancer treatment.
May 13, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Applied DNA's technology being used for CAR T-cell therapy manufacture could signal a significant advancement in cancer treatment, potentially boosting the company's profile and market opportunities.
The use of Applied DNA's technology in a significant medical advancement like CAR T-cell therapy for AML underlines the company's role in critical healthcare innovations. This could lead to increased interest from the medical community and investors, highlighting the company's potential for growth and partnership in the biotech and healthcare sectors.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90